{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T19:11:50Z","timestamp":1775243510862,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.vaccine.2025.127645","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:24Z","timestamp":1756929144000},"page":"127645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Adopting the estimand framework in prophylactic vaccine trials"],"prefix":"10.1016","volume":"64","author":[{"given":"Francois","family":"Beckers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naveen","family":"Karkada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Klinglm\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Fay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Englert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Spiessens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Van Dromme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tulin","family":"Shekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiqi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Casula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Janes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence H.","family":"Moulton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127645_bb0005","author":"ICH Harmonised Guideline"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127645_bb0010","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s43441-022-00402-3","article-title":"Marking 2-years of new thinking in clinical trials: the Estimand journey","volume":"56","author":"Fletcher","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127645_bb0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pst.1917","article-title":"Treatment effect quantification for time-to-event endpoints\u2013Estimands, analysis strategies, and beyond","volume":"18","author":"Rufibach","year":"2019","journal-title":"Pharm Stat"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127645_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(20)30319-3","article-title":"Demystifying the estimand framework: a case study using patient-reported outcomes in oncology","volume":"21","author":"Fiero","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127645_bb0025","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.2158","article-title":"Estimands for overall survival in clinical trials with treatment switching in oncology","volume":"21","author":"Manitz","year":"2022","journal-title":"Pharm Stat"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127645_bb0030","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/pst.2319","article-title":"Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development","volume":"22","author":"Englert","year":"2023","journal-title":"Pharm Stat"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127645_bb0035","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(19)30407-3","article-title":"Estimands in diabetes clinical trials","volume":"8","author":"Min","year":"2020","journal-title":"The Lancet Diabetes & Endocrinol"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127645_bb0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1001\/jama.2021.2886","article-title":"Estimands, estimators, and estimates","volume":"326","author":"Little","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127645_bb0045","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1097\/j.pain.0000000000001937","article-title":"Estimands and missing data in clinical trials of chronic pain treatments: advances in design and analysis","volume":"161","author":"Cai","year":"2020","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127645_bb0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10543406.2023.2197040","article-title":"Application of estimand framework in ICH E9 (R1) to vaccine trials","volume":"33","author":"Fu","year":"2023","journal-title":"J Biopharm Stat"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127645_bb0055","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2024.01.005","article-title":"Estimand for non-inferiority influenza vaccine immunogenicity trials","volume":"42","author":"Nauta","year":"2024","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127645_bb0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/19466315.2023.2211538","article-title":"Vaccine development during a pandemic: general lessons for clinical trial design","volume":"16","author":"Hofner","year":"2024","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127645_bb0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0264-410X(00)00152-3","article-title":"Intent-to-treat analysis and preventive vaccine efficacy","volume":"19","author":"Horne","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2025.127645_bb0070","article-title":"Design of vaccine efficacy trials during public health emergencies","volume":"11(499):eaat0360","author":"Dean","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127645_bb0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/19466315.2021.1919197","article-title":"Statistical observations on vaccine clinical development for pandemic diseases","volume":"14","author":"Patterson","year":"2022","journal-title":"Stat Biopharm Res"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127645_bb0080","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1191\/0962280204sm356ra","article-title":"Endpoints in vaccine trials","volume":"13","author":"Hudgens","year":"2004","journal-title":"Stat Methods Med Res"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127645_bb0085","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/oxfordjournals.aje.a009196","article-title":"Study designs for evaluating different efficacy and effectiveness aspects of vaccines","volume":"146","author":"Halloran","year":"1997","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127645_bb0090","article-title":"Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials. Stat Commun","volume":"14","author":"Michiels","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127645_bb0095","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s43441-019-00061-x","article-title":"Choosing Estimands in clinical trials: putting the ICH E9(R1) into practice","volume":"54","author":"Ratitch","year":"2020","journal-title":"Ther Innov Regul Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127645_bb0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/17407745231160074","article-title":"Using modified intention-to-treat as a principal stratum estimator for failure to initiate treatment","volume":"20","author":"Kahan","year":"2023","journal-title":"Clin Trials"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127645_bb0105","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/pst.2104","article-title":"Principal stratum strategy: Potential role in drug development","volume":"20","author":"Bornkamp","year":"2021","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127645_bb0110","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/pst.1909","article-title":"Strategies for composite estimands in confirmatory clinical trials: examples from trials in nasal polyps and steroid reduction","volume":"18","author":"Keene","year":"2019","journal-title":"Pharm Stat"},{"issue":"16","key":"10.1016\/j.vaccine.2025.127645_bb0115","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1002\/sim.9405","article-title":"Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated","volume":"41","author":"Follmann","year":"2022","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127645_bb0120","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.7326\/M20-8149","article-title":"A deferred-vaccination design to assess durability of COVID-19 vaccine effect after the placebo group is vaccinated","volume":"174","author":"Follmann","year":"2021","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127645_bb0125","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/sim.1039","article-title":"Statistical approaches to establishing vaccine safety","volume":"21","author":"Dragalin","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2025.127645_bb0130","series-title":"Statistics in clinical vaccine trials","author":"Nauta","year":"2010"},{"issue":"27","key":"10.1016\/j.vaccine.2025.127645_bb0135","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1002\/sim.9001","article-title":"Assessing vaccine durability in randomized trials following placebo crossover","volume":"40","author":"Fintzi","year":"2021","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127645_bb0140","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/biom.13509","article-title":"Estimating vaccine efficacy over time after a randomized study is unblinded","volume":"78","author":"Tsiatis","year":"2021","journal-title":"Biometrics"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127645_bb0145","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1093\/cid\/ciab226","article-title":"Evaluating the long-term efficacy of coronavirus disease 2019 (COVID-19) vaccines","volume":"73","author":"Lin","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"21\u221222","key":"10.1016\/j.vaccine.2025.127645_bb0150","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/(SICI)1097-0258(19961115)15:21<2379::AID-SIM457>3.0.CO;2-L","article-title":"Comparing methods for calculating confidence intervals for vaccine efficacy","volume":"15","author":"Ewell","year":"1996","journal-title":"Stat Med"},{"issue":"8","key":"10.1016\/j.vaccine.2025.127645_bb0155","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1080\/03610929408831393","article-title":"Correcting for non-compliance in randomized trials using structural nested mean models","volume":"23","author":"Robins","year":"1994","journal-title":"Communications in Statistics - Theory and Methods"},{"issue":"4","key":"10.1016\/j.vaccine.2025.127645_bb0160","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1214\/14-STS493","article-title":"Structural nested models and G-estimation: the partially realized promise","volume":"29","author":"Vansteelandt","year":"2014","journal-title":"Stat Sci"},{"key":"10.1016\/j.vaccine.2025.127645_bb0165","author":"ICH Harmonised Guideline"},{"key":"10.1016\/j.vaccine.2025.127645_bb0170","article-title":"Committee for Medicinal Products for human use (CHMP). Guideline on missing data in confirmatory clinical trials","year":"2010","journal-title":"EMA\/CPMP\/EWP\/1776\/99 Rev. 1."},{"key":"10.1016\/j.vaccine.2025.127645_bb0175","series-title":"Statistical analysis with missing data","author":"Little","year":"2002"},{"key":"10.1016\/j.vaccine.2025.127645_bb0180","series-title":"Missing data in clinical studies","author":"Molenberghs","year":"2007"},{"key":"10.1016\/j.vaccine.2025.127645_bb0185","series-title":"Handbook of missing data methodology","author":"Molenberghs","year":"2014"},{"issue":"14","key":"10.1016\/j.vaccine.2025.127645_bb0190","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1056\/NEJMsr1203730","article-title":"The prevention and treatment of missing data in clinical trials","volume":"367","author":"Little","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127645_bb0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/17407745231176773","article-title":"Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: a tuberculosis case study","volume":"20","author":"Rehal","year":"2023","journal-title":"Clin Trials"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127645_bb0200","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1080\/10543406.2013.834911","article-title":"Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation","volume":"23","author":"Carpenter","year":"2013","journal-title":"J Biopharm Stat"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127645_bb0205","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/17407745221080463","article-title":"Incorporating estimands into clinical trial statistical analysis plans","volume":"19","author":"Kang","year":"2022","journal-title":"Clin Trials"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25009429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:53:01Z","timestamp":1769025181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25009429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":41,"alternative-id":["S0264410X25009429"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127645","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adopting the estimand framework in prophylactic vaccine trials","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127645","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127645"}}